Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinet...Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinetic basis of approval and dearth of long-term safety data. The brevity and relatively reduced cost of pharmacokinetic based registration trials provides little commercial incentive to develop improved novel therapies for the treatment of late onset male hypogonadism. Selective androgen receptor modulators （SARMs） have been shown to provide anabolic benefit in the absence of androgenic effects on prostate, hair and skin. Current clinical development for SARMs is focused on acute muscle wasting conditions with defined clinical endpoints of physical function and lean body mass. Similar regulatory clarity concerning clinical deficits in men with hypogonadism is required before the beneficial pharmacology and desirable pharmacokinetics of SARMs can be employed in the treatment of late onset male hypogonadism.展开更多
Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the au...Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the authors evaluate a novel set of genes associated with senescence and aging as tools that can provide guidance regarding the indolent nature of an individual＇s prostate cancer with validation using both mRNA and protein analyses. While additional studies are required to understand the full impact of these findings, the innovative approach taken enhances our understanding of distinct phenotypes of prostate cancer.展开更多
Advancing supercapacitor system performance hinges on the innovation of novel electrode materials seamlessly integrated within distinct architectures.Herein,we introduce a direct approach for crafting nanorod arrays f...Advancing supercapacitor system performance hinges on the innovation of novel electrode materials seamlessly integrated within distinct architectures.Herein,we introduce a direct approach for crafting nanorod arrays featuring crystalline/amorphous CuO/MnO_(2)−x.This reconfigured heterostructure results in an elevated content of electrochemically active MnO_(2).The nanorod arrays serve as efficient capacitive anodes and are easily prepared via low-potential electrochemical activation.The resulting structure spontaneously forms a p–n heterojunction,developing a built-in electric field that dramatically facilitates the charge transport process.The intrinsic electric field,in conjunction with the crystalline/amorphous architecture,enables a large capacitance of 1.0 F·cm^(−2)at 1.0 mA·cm^(−2),an ultrahigh rate capability of approximately 85.4%at 15 mA·cm^(−2),and stable cycling performance with 92.4%retention after 10,000 cycles.Theoretical calculations reveal that the presence of heterojunctions allows for the optimization of the electronic structure of this composite,leading to improved conductivity and optimized OH−adsorption energy.This work provides new insights into the rational design of heterogeneous nanostructures,which hold great potential in energy storage applications.展开更多
文摘Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinetic basis of approval and dearth of long-term safety data. The brevity and relatively reduced cost of pharmacokinetic based registration trials provides little commercial incentive to develop improved novel therapies for the treatment of late onset male hypogonadism. Selective androgen receptor modulators （SARMs） have been shown to provide anabolic benefit in the absence of androgenic effects on prostate, hair and skin. Current clinical development for SARMs is focused on acute muscle wasting conditions with defined clinical endpoints of physical function and lean body mass. Similar regulatory clarity concerning clinical deficits in men with hypogonadism is required before the beneficial pharmacology and desirable pharmacokinetics of SARMs can be employed in the treatment of late onset male hypogonadism.
文摘Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the authors evaluate a novel set of genes associated with senescence and aging as tools that can provide guidance regarding the indolent nature of an individual＇s prostate cancer with validation using both mRNA and protein analyses. While additional studies are required to understand the full impact of these findings, the innovative approach taken enhances our understanding of distinct phenotypes of prostate cancer.
基金financially supported by the National Natural Science Foundation of China(Nos.52272181,51872016,and 52201261).
文摘Advancing supercapacitor system performance hinges on the innovation of novel electrode materials seamlessly integrated within distinct architectures.Herein,we introduce a direct approach for crafting nanorod arrays featuring crystalline/amorphous CuO/MnO_(2)−x.This reconfigured heterostructure results in an elevated content of electrochemically active MnO_(2).The nanorod arrays serve as efficient capacitive anodes and are easily prepared via low-potential electrochemical activation.The resulting structure spontaneously forms a p–n heterojunction,developing a built-in electric field that dramatically facilitates the charge transport process.The intrinsic electric field,in conjunction with the crystalline/amorphous architecture,enables a large capacitance of 1.0 F·cm^(−2)at 1.0 mA·cm^(−2),an ultrahigh rate capability of approximately 85.4%at 15 mA·cm^(−2),and stable cycling performance with 92.4%retention after 10,000 cycles.Theoretical calculations reveal that the presence of heterojunctions allows for the optimization of the electronic structure of this composite,leading to improved conductivity and optimized OH−adsorption energy.This work provides new insights into the rational design of heterogeneous nanostructures,which hold great potential in energy storage applications.
